Skip to content
ENT SurgicalTech & Protocols

Optimizing Neuromuscular Blockade for Reliable RLN Monitoring in Thyroid Surgery

RCT comparing cisatracurium (1×ED95) vs succinylcholine (5×ED95) for intubation in thyroid surgery: succinylcholine yields superior intubation and immediate RLN signal availability.

IP

Editorial Team

Clinical evidence review

6 min read
Source:Journal of Cancer Control and Treatment (2020)DOI10.3969/j.issn.1674-0904.2020.07.005

Key Takeaways

  • Succinylcholine (5×ED95, 1.5 mg/kg) produced uniformly excellent intubation conditions (Cooper score 9.00 ± 0.00) versus only "good" conditions with low-dose cisatracurium (1×ED95, 0.05 mg/kg; 6.50 ± 0.60; P < 0.001).
  • Intubation time was markedly shorter with succinylcholine (3.1 ± 0.8 min vs 8.4 ± 1.3 min; P < 0.001), and neuromuscular monitoring could begin sooner (27.2 ± 3.5 min vs 32.3 ± 4.2 min; P < 0.001).
  • All 52 succinylcholine patients (100%) had an RLN monitoring signal available at first surgical exploration, versus only 37 of 51 (72.5%) cisatracurium patients (P < 0.001).
  • Sore throat was more frequent with cisatracurium (17/51, 33.3% vs 8/52, 15.4%; P = 0.030), while postoperative myalgia trended higher with succinylcholine (5/52, 9.6% vs 0/51; P = 0.060) but did not reach significance.

Clinical Context

Intraoperative Neurophysiological Monitoring (IONM) reduces the incidence of Recurrent Laryngeal Nerve (RLN) injury during thyroidectomy and supports real-time surgical decision-making. However, neuromuscular blocking agents (NMBAs) used for endotracheal intubation directly suppress the EMG signals on which IONM depends. This creates a fundamental tension between two clinical priorities:

  1. The anesthesiologist requires adequate muscle relaxation for safe, rapid tracheal intubation—particularly with an EMG Endotracheal Tube (EMG Tube).
  2. The surgeon requires recovered vocal cord muscle function to obtain reliable V1, R1, R2, and V2 signals during nerve dissection.

Clinical IONM guidelines have recommended a reduced induction dose of cisatracurium (0.05 mg/kg, ~1×ED95) to preserve monitorability. Yet this sub-paralyzing dose degrades intubation conditions, prolongs induction, and—critically—may leave residual neuromuscular blockade (NMB) at the moment the surgeon first probes the RLN. This randomized controlled trial from a high-volume tertiary surgical center compared the guideline-recommended low-dose cisatracurium against the clinically standard 5×ED95 succinylcholine (1.5 mg/kg) to quantify the trade-offs for both teams.

Clinical Evidence & Cohort Breakdown

This was a prospective, single-center randomized controlled trial enrolling 103 patients (30 male, 73 female; age 18–72) undergoing elective thyroid surgery with RLN monitoring. Patients were randomized to Group C (cisatracurium 0.05 mg/kg, n = 51) or Group S (succinylcholine 1.5 mg/kg, n = 52). Inclusion required first-time surgery, a single surgical team, and preoperatively normal vocal cord mobility on electronic nasopharyngoscopy. Reoperation, contraindications to NMBAs, and pre-existing RLN injury or vocal cord pathology were excluded.

Baseline characteristics were well matched:

Variable Group C (n = 51) Group S (n = 52) Statistical Value P
Sex (male/female) 13/38 17/35 χ² = 0.710 0.400
Age (years) 39.8 ± 12.9 39.9 ± 12.2 t = −0.04 0.970
Body mass index 23.8 ± 2.4 23.1 ± 2.7 t = 1.29 0.200
Drug-related hypertension 7 10 χ² = 0.566 0.450

Intubation and monitoring outcomes:

Variable Group C (n = 51) Group S (n = 52) t P
Cooper intubation score 6.50 ± 0.60 9.00 ± 0.00 30.730 < 0.001
Intubation time (min) 8.4 ± 1.3 3.1 ± 0.8 −24.988 < 0.001
Neuromuscular monitoring time (min) 32.3 ± 4.2 27.2 ± 3.5 −6.728 < 0.001
Surgical monitoring time (min) 23.5 ± 3.9 24.1 ± 3.3 0.354 0.725

Intubation time: from NMBA injection to completed intubation. Neuromuscular monitoring time: from NMBA injection to start of RLN monitoring. Surgical monitoring time: from skin disinfection to start of RLN monitoring.

First-signal availability and intraoperative events:

Variable Group C (n = 51) Group S (n = 52) χ² P
First-attempt monitoring signal present 37 (72.5%) 52 (100%) 16.520 < 0.001
Intraoperative blood pressure drop 12 16 0.682 0.409
Intraoperative body movement 0 0 — —

Postoperative complications:

Variable Group C (n = 51) Group S (n = 52) Test Statistic P
Hoarseness 0 0 — —
Sore throat 17 (33.3%) 8 (15.4%) 4.513 0.030
Myalgia 0 5 (9.6%) — 0.060

Notably, the difference in neuromuscular monitoring time was attributable almost entirely to the prolonged intubation in Group C. Once intubation delay was accounted for, surgical monitoring time (disinfection to RLN exploration) was statistically indistinguishable between groups (P = 0.725)—reflecting the high operative efficiency of the participating center, where rapid exposure outpaced cisatracurium metabolism.

Intraoperative IONM Protocol & Technical Pearls

The following stepwise protocol reflects the study methodology and can be adapted to centers performing RLN-monitored thyroidectomy.

  1. Preoperative verification. Confirm normal vocal cord mobility and absence of hoarseness by electronic nasopharyngoscopy to establish a baseline and exclude pre-existing RLN injury.
  2. Standardized anesthetic induction. Premedicate with atropine (antisialagogue) and a dexmedetomidine infusion. Induce with midazolam 0.04 mg/kg, sufentanil 0.5 μg/kg, and propofol 1.5 mg/kg. After loss of consciousness, administer the NMBA per randomization: cisatracurium 0.05 mg/kg (guideline dose) or succinylcholine 1.5 mg/kg (clinical dose).
  3. Quantitative neuromuscular monitoring. Apply neuromuscular monitoring and confirm maximal suppression before intubation. Use an EMG Endotracheal Tube placed by an anesthesiologist with ≥5 years of experience; verify tube positioning and electrode contact.
  4. Electrode placement and system check. Insert Subdermal Needle Electrodes subcutaneously over the chest as the reference electrode and secure them. Connect the nerve monitor and confirm correct electrode alignment and signal integrity before incision.
  5. Maintain stable anesthesia. Use sevoflurane, propofol, remifentanil, and dexmedetomidine, with depth titrated to a Narcotrend D1–D2 state and intermittent analgesia. Avoid additional NMBA that would suppress EMG.
  6. Standardized stimulation sequence. Stimulate the Vagus Nerve (VN) at 3 mA and the RLN at 1 mA. Record the presence and timing of evoked EMG responses (V1, R1, R2, V2) and document EMG Amplitude (μV) and Latency (ms).
  7. Anticipate signal recovery. When using low-dose cisatracurium, expect that a proportion of patients (~27.5% in this cohort) will not yet have a monitorable signal at first exploration; be prepared to wait for further NMB recovery before interpreting Loss of Signal (LOS).
  8. Adjunct measures. Administer intravenous dexamethasone intraoperatively to reduce nerve edema, and use standardized antiemetic prophylaxis.

Clinical Implications for Surgeons & IONM Specialists

  • Succinylcholine (5×ED95) resolves the intubation–monitoring conflict. It delivered uniformly excellent intubation conditions, cut induction time by more than half, and guaranteed an immediately available RLN signal at first exploration—eliminating the "wait for NMB recovery" period that can delay or confound initial nerve assessment.
  • Low-dose cisatracurium carries a hidden monitoring cost. Although the guideline dose preserves eventual monitorability, roughly one in four patients lacked a first-attempt signal, forcing the surgical team to distinguish True-Positive LOS from residual NMB before drawing conclusions about nerve integrity.
  • Intubation quality affects patient comfort. The poorer Cooper scores and higher sore throat rate (33.3% vs 15.4%) with low-dose cisatracurium reflect more difficult, traumatic intubation—a clinically meaningful downstream penalty.
  • Myalgia with succinylcholine is modest and manageable. The 9.6% incidence was non-significant and likely attenuated by intraoperative dexamethasone, sufentanil, and non-steroidal analgesia; nonetheless, strict adherence to succinylcholine indications (e.g., caution in hyperkalemia risk, burns, or neuromuscular disease) remains essential.
  • Operative volume matters. The center's high thyroidectomy caseload shortened the interval from disinfection to nerve exploration, paradoxically leaving insufficient time for cisatracurium to metabolize—a reminder that drug-timing assumptions must be calibrated to local workflow speed.
  • Practical takeaway for the OR team. Where rapid, high-quality intubation and immediate signal availability are priorities, succinylcholine at clinical dose is a rational choice; where it is contraindicated, plan for longer induction and a deliberate NMB-recovery interval before interpreting early RLN signals. Continuous IONM (C-IONM) and careful V1 baseline confirmation further protect against False-Positive LOS.

Limitations: This was a single-center study; multicenter confirmation of efficacy and safety is warranted.

Reference

Xu YQ, Qing XY, Zhang KX, Wang CJ, Chen YD, Wang HM, Zhang HW, Shu JJ, Li C. A randomized controlled trial of muscle relaxants in recurrent laryngeal nerve monitoring during thyroid surgery. Journal of Cancer Control and Treatment. 2020;33(7):573–577. doi: 10.3969/j.issn.1674-0904.2020.07.005

Medical Disclaimer: This article is provided for educational and informational purposes only and does not constitute medical advice. Clinical protocols, drug dosing, and monitoring practices should be individualized to each patient and institution, and verified against current local guidelines and prescribing information. The editorial team assumes no liability for clinical decisions made on the basis of this content.

Medical disclaimer

This protocol is provided for clinical education and reference only. It does not constitute medical advice, a standard of care, or a substitute for surgeon judgment, institutional policy, device labeling, or patient-specific assessment. Verify all stimulation parameters, electrode compatibility and indications against current manufacturer instructions before use. Read the full disclaimer.

Continue the protocol

Related guidance

View the IONM library